A biomarker is a measurable biological indicator, typically a specific protein, molecule, isotope, or metabolic by-product, found in bodily fluids such as blood or cerebrospinal fluid. When disease begins to develop, it triggers changes at the molecular level long before any physical symptom surfaces. Instruments like spectrometers and chromatographs can detect these minute chemical shifts with precision.
The clinical value of this is considerable. Blood-based biomarker assays allow physicians to move from late-stage symptomatic management to early molecular triage, without the pain and risk of invasive procedures. A lumbar puncture, or an expensive PET (Positron Emission Tomography) scan, can now potentially be replaced or supplemented by a blood test.
For neurological conditions, this shift matters most. Elevated levels of Tau (p-tau217) and Amyloid-beta in the blood track the buildup of abnormal plaques and neurofibrillary tangles associated with Alzheimer's disease. Alpha-synuclein detects misfolded protein clumps linked to the nerve-cell loss that drives Parkinson's. Neurofilament Light (NfL), while less disease-specific, serves as a sensitive indicator of neuroaxonal injury across a range of neurological disorders. Beyond diagnosis, serial biomarker testing allows doctors to monitor how a patient responds to treatment over time, making it a tool for precision medicine as much as for detection.
India's ability to use these tools effectively depends on whether its reference data reflects its own population. Most existing biomarker norms have been derived from Western cohorts, which differ from South Asian populations in genetics, diet, environment, and disease burden. Two initiatives are working to correct this.
The GenomeIndia Project, launched in January 2020 and funded by the Department of Biotechnology (DBT), has completed whole-genome sequencing of over 10,000 individuals drawn from diverse Indian populations. It provides a critical foundation for identifying population-specific biomarkers and genetic risk factors relevant to South Asians.
The Indian Institute of Science (IISc) Longevity India Programme has launched the BHARAT Study (Biomarkers of Healthy Aging, Resilience, Adversity, and Transitions) with the explicit aim of establishing a "Bharat Baseline." Chronological age alone does not accurately reflect biological age, since ageing is shaped by molecular, cellular, environmental, and socioeconomic factors. The BHARAT Study seeks to develop biomarkers that capture ageing patterns specific to Indians, reducing dependence on norms that may not apply here.
Despite this momentum, the structural challenges are serious. Many biomarkers lack absolute specificity. NfL, for instance, signals nerve damage but cannot identify which disease is causing it. Confounding variables like age, kidney function, and concurrent medications can skew results, raising the risk of false positives or false negatives. The immunoassay platforms required for accurate testing are expensive and largely confined to major metropolitan centres; district and rural hospitals rarely have the automated equipment these tests demand.
There is also no uniform standard governing how laboratories conduct and interpret biomarker tests. Variations in method and equipment across facilities mean that the same patient could receive different readings in different cities.
The ethical dimension is equally pressing. Identifying a preclinical disease in an asymptomatic individual creates what researchers call a "patient-in-waiting," someone who may face psychological distress and, if their results enter medical records without legal protection, potential discrimination in insurance or employment.
Addressing these gaps requires coordinated institutional action. The Indian Council of Medical Research (ICMR) and the Central Drugs Standard Control Organisation (CDSCO) need to establish unified clinical guidelines and standard operating procedures for biomarker testing across laboratories. Indigenous research in diagnostic reagents must be supported to reduce dependence on costly imported platforms, and diagnostic infrastructure must be expanded to the district hospital level with trained personnel capable of interpreting results. A clear legal framework governing genetic and biomarker data privacy, one that explicitly protects asymptomatic individuals from discrimination, is not optional. It is a precondition for public trust in these technologies.
With reference to the GenomeIndia Project, which of the following statements is correct?
Which of the following best describes the purpose of the BHARAT Study launched under the IISc Longevity India Programme?
With reference to the ethical concerns around biomarker testing discussed in the article, which of the following is identified as a key risk for asymptomatic individuals whose results enter medical records without legal protection?
